Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock to Neutral, setting a price target of $63. Wolfe Research also initiated Peer Perform rating. Additionally, Daiwa Securities raised Outperform rating on November 13, 2024. Leerink Partners analysts, in their report published on November 12, 2024, also raised Outperform rating and set a price target of $73 for Bristol-Myers Squibb Co’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Bristol-Myers Squibb Co (BMY) Stock Trading Recap
On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and touched a low of $55.46 during the day, reaching a high of $55.98. The volume of shares traded was 7.35 million falling short of the average volume of 10.58 million.
Sponsored
BMY Stock Performance and Moving Averages
In recent trading, Bristol-Myers Squibb Co (BMY) stock price has shown some volatility, fluctuating -1.66% over the last five trades and -1.61% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 38.83%, and it has gained 6.78% in the previous three months. Currently, BMY is trading at -1.72%, -2.65%, and 12.58% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, BMY, a Healthcare sector stock, is trading -8.74% below its 52-week high but remains 41.65% above its 52-week low. The Average True Range (ATR) (14 days) of 1.1 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Bristol-Myers Squibb Co’s Profitability and Valuation Ratios
Bristol-Myers Squibb Co’s profitability metrics reveal financial health. The company currently boasts an operating margin of 17.62% and a profit margin of -15.30%, with a gross margin of 38.83%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Bristol-Myers Squibb Co’s market capitalization stands at $113.05 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 7.96. Additionally, the Price-to-Sales Ratio is 2.38, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 6.59, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.08% of Bristol-Myers Squibb Co (BMY)’s shares, while financial institutions hold 77.74%.